Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaPre in Severe Hypertriglyceridemia
NCT03398005Phase 3Completed
- Sponsor
- Grace Therapeutics, Inc.
- Start
- Jan 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CaPre in hypertriglyceridemia, sponsored by Grace Therapeutics, Inc.. Started Jan 2018; status: completed.
02
Drugs
CaPre
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT03398005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398005.